Navigation Links
SRI International Receives $9 Million Contract to Support National Cancer Institute PREVENT Cancer Program
Date:11/2/2015

MENLO PARK, Calif., Nov. 2, 2015 /PRNewswire/ -- SRI International has been awarded a contract of up to $9 million to provide preclinical development services to the National Cancer Institute (NCI) PREVENT Cancer Program (PCP). Under the contract, SRI will provide scientific expertise, modern testing and support facilities, and analytical instrumentation to conduct a wide variety of preclinical pharmacology and toxicology studies to evaluate potential cancer prevention drugs.

The PREVENT Cancer Drug Development Program is an NCI-supported pipeline to bring new cancer preventing interventions and biomarkers through preclinical development towards clinical trials. PREVENT enables milestone-driven progression of novel cancer preventive chemical or biological agents and biomarkers from the laboratory bench towards proof-of-principle clinical testing and registration or validation.

"We welcome the opportunity to provide preclinical toxicology and pharmacology services to support the NCI's PREVENT program," said Toufan Parman, Ph.D., D.A.B.T, director, General Toxicology, SRI Biosciences, and principal investigator for the NCI contract. "We've provided such services to the NCI for the past 23 years, and look forward to continue applying our expertise to this important work."

The current contract calls for SRI to deliver high-quality laboratory data to support NCI-PCP's efforts to develop promising therapeutic candidates such as vaccines and cancer chemopreventive agents that will inhibit, delay or reverse manifestations of cancer. SRI will be responsible for managing therapeutic candidates from conception to submission of an Investigational New Drug (IND) application to the US Food and Drug Administration. SRI has broad experience with similar studies for NCI and for many other divisions of the National Institutes of Health, as well as for private sponsors.

This effort is fully funded by the National Cancer Institute.

About SRI Biosciences
SRI Biosciences, a division of SRI International, integrates basic biomedical research with drug and diagnostics discovery and preclinical and clinical development. SRI International, a research center headquartered in Menlo Park, California, creates world-changing solutions making people safer, healthier, and more productive.

 


'/>"/>
SOURCE SRI International
Copyright©2015 PR Newswire.
All rights reserved


Related biology news :

1. CLEO: 2013 -- the Premier International Laser and Electro-Optics Event in San Jose next week
2. SPIE on global team proposing International Year of Light at United Nations
3. First international collaboration to showcase latest body of evidence of dairy health benefits
4. PETA International Science Consortium disappointed in denial of Dow appeal
5. 4th International Nanomedicine Conference
6. Efficacy of acupressure to relieve migraine nausea presented at International Headache Congress
7. MARC travel awards announced for the GSA: 19th International C. elegans Meeting
8. UChicago Celiac Disease Center to host international symposium
9. Researchers describe potential for MERS coronavirus to spread internationally
10. SmartMove, Inc. receives $200,000 grant from the Colorado Office of Economic Development and International Trade
11. International Rett Syndrome Foundation chief science officer receives prestigious military awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2020)... (PRWEB) , ... March 09, ... ... enterprises witnessed a steep growth rate of 64% last year, as enterprises ... new research from Everest Group. Unfortunately, only 13% of all transformation efforts ...
(Date:3/5/2020)... ... 2020 , ... In September 2016, stem cell biotechnology company ... the first, and still only, available technology that provides the cell-specific count or ... about the number and quality of therapeutic tissue stem cells are unable to ...
(Date:3/3/2020)... HILLS, Calif. (PRWEB) , ... March 03, 2020 , ... ... spinal levels with the dualX Expanding Interbody Fusion System. , The landmark ... Fresno, CA. After the case Dr. Najafi noted, “dualX has completely changed the ...
Breaking Biology News(10 mins):
(Date:3/10/2020)... ... March 10, 2020 , ... ... to announce the addition of Carson Dickey to its growing engineering team. ... the biopharmaceutical cold chain. He provides design and validation engineering services by ...
(Date:3/4/2020)... , ... March 04, 2020 ... ... an industry-leading provider of recombinant antibody products and services, today announced the ... the flexibility to rapidly express a large number of antibodies at 80 ...
(Date:3/3/2020)... ... 03, 2020 , ... Frictionless Solutions, a specialized event services ... recognized by INC. 5,000 on an annual list of America’s fastest growing private ... impacting their spheres of influence and experiencing considerable development. INC. 5,000’s specific list ...
(Date:3/2/2020)... Md. (PRWEB) , ... March 02, 2020 , ... McBee, ... Patent Firms 2019 list in the field of Biotechnology and Organics. , According to ... on a total of 259 patents issued in technology center 1600 during 2019. Technology ...
Breaking Biology Technology: